Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-guided individualized neoadjuvant therapy for adenocarcinoma of the gastroesophageal junction
2014-000860-16Phase 2Completed
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Mar 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, oxaliplatin, epirubicin, carboplatin, capecitabine and 3 more in gastroesophageal junction adenocarcinoma and gastrointestinal cancer, sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: R0 resection rate. Started Mar 2014; status: completed.
02
Drugs
paclitaxeloxaliplatinepirubicincarboplatincapecitabine
03
Conditions
gastroesophageal junction adenocarcinomagastrointestinal cancer
Beyond the preview
Go deeper on 2014-000860-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000860-16.